Together, our findings demonstrate the significance of FLT3 as a therapeutic target in BP progression and propose targeting FLT3 and downstream effectors are viable treatment strategies for preventing and overcoming TKI resistance in advanced phase CML. Here, FLT3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.